FUNDAMENTALS · Fundamentals · US Healthcare

Myriad Genetics (MYGN) Fundamentals 2026 — Revenue Analysis | SniperIQ

Myriad Genetics (MYGN) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of $536M, trading at $5.67 on the NASDAQ. This SniperIQ fundamentals page covers Myriad Genetics's valuation, profitability (net margin -48.2%), revenue ($825M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$536M
Net Margin-48.2%
Revenue (FY25)$825M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Myriad Genetics's market cap?

Myriad Genetics (MYGN) has a market capitalization of approximately $536M, trading at $5.67 on the NASDAQ. Market cap moves with the live share price.

What is Myriad Genetics's P/E ratio?

Myriad Genetics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Myriad Genetics?

Myriad Genetics runs a net profit margin of -48.2%, a gross margin of 70.0%, and an operating margin of -46.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Myriad Genetics generate?

Myriad Genetics reported revenue of $825M for fiscal year 2025, with net income of -

66M and earnings per share (EPS) of -3.96. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Myriad Genetics pay a dividend?

Myriad Genetics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Myriad Genetics financially healthy?

Myriad Genetics carries a debt-to-equity ratio of 0.63x and a current ratio of 2.40x, with a market beta of 1.64. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Myriad Genetics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Myriad Genetics (MYGN) the key facts are: market cap $536M, revenue $825M, 52-week range 3.53-8.59. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Myriad Genetics's full fundamentals live

Get Myriad Genetics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.